The article discusses the development of synthetic immune chimeric antiJOUR receptor T (CAR T) cells as a treatment for cancer, including through offering a diagram. An overview of the JOURetic engineering of CAR T cells to treat cancer, including the JOURetic modification of T cells to target the antiJOUR, is provided.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados